Victory Capital Management
CRVS icon

Victory Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Victory Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.3M Buy
220,761
+92,409
+72% +$1.28M ﹤0.01% 1491
2026
Q1 		$1.88M Buy
+128,352
New +$2.05M ﹤0.01% 1614
2020
Q2 		– Sell
-4,017
Closed -$8K – 2685
2020
Q1 		$8K Buy
+4,017
New +$16.3K ﹤0.01% 3144
2019
Q4 		– Sell
-3,538
Closed -$11K – 2780
2019
Q3 		$11K Buy
+3,538
New +$14.8K ﹤0.01% 3223

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Victory Capital Management's CRVS Position: Q2 2026 in Review

Victory Capital Management increased its Corvus Pharmaceuticals (CRVS) stake by 72% in Q2 2026, buying an estimated $1.28M and bringing the position to 220,761 shares worth $3.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1491.

Victory Capital Management first reported a position in CRVS in Q3 2019 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Victory Capital Management held 220,761 shares of Corvus Pharmaceuticals worth $3.3M as of Q2 2026.
  • Victory Capital Management bought 92,409 Corvus Pharmaceuticals shares in Q2 2026, an estimated $1.28M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1491 holding.
  • Victory Capital Management first reported a position in Corvus Pharmaceuticals in Q3 2019 and has held it in 4 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.